Clarifying haplotype ambiguity of NAT2 in multi-national cohorts

Frontiers in Bioscience - Scholar

Volumn 5 S, Issue 2, 2013, Pages 672-684

  Selinski, Silvia ^a   Blaszkewicz, Meinolf ^a   Agundez, Jose A G ^b   Martinez, Carmen ^b   Garcia Martin, Elena ^b   Hengstler, Jan G ^a   Golka, Klaus ^a  

^a LEIBNIZ RESEARCH CENTRE FOR WORKING ENVIRONMENT AND HUMAN FACTORS   (Germany)

^b UNIVERSITY OF EXTREMADURA   (Spain)

Author keywords

Rs1041983 (C282T); Rs1208 (A803G); Rs1799929 (C481T); Rs1799930 (G590A); Rs1799931 (G857A); Rs1801279 (G191A); Rs1801280 (T341C)

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; NAT2 PROTEIN, HUMAN;

ACETYLATION; ARTICLE; BLADDER CANCER; CANCER RISK; COLON CANCER; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; ETHNIC DIFFERENCE; GENE ASSIGNMENT; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GERMANY; HAPLOTYPE; HEAD AND NECK CANCER; HIP OSTEOARTHRITIS; HUMAN; HUNGARY; KIDNEY CARCINOMA; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; PAKISTAN; POPULATION GENETICS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SPAIN; VENEZUELA; ALLELE; ASIAN; BLADDER TUMOR; CAUCASIAN; COHORT ANALYSIS; ENZYMOLOGY; ETHNOLOGY; EUROPE; GENETIC PREDISPOSITION; GENETICS; METABOLISM; REPRODUCIBILITY;

ACETYLATION; ALLELES; ARYLAMINE N-ACETYLTRANSFERASE; ASIAN CONTINENTAL ANCESTRY GROUP; COHORT STUDIES; EUROPE; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; PAKISTAN; POLYMORPHISM, SINGLE NUCLEOTIDE; REPRODUCIBILITY OF RESULTS; URINARY BLADDER NEOPLASMS;

EID: 84883733778     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: 10.2741/s399     Document Type: Article

References (97)

1. DW Hein: N-Acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexities of personalized medicine. Expert Opin Drug Metab Toxicol 5, 353-366 (2009)
2. DW Hein: Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat Res 506-507, 65-77 (2002)
3. DW Hein: N-Acetyltransferase genetics and their role in predisposition to aromatic and heterocyclic amine-induced carcinogenesis. Toxicol Lett 112-113, 349-56 (2000)
4. HB Hughes, JB Biehl, AP Jones, LH Schmidt: Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis. Am Rev Tuberc 70, 266-273 (1954)
5. RS Mitchell, JC Bell: Clinical implications of isoniazid blood levels in pulmonary tuberculosis. N Engl J Med 257, 1066-1070 (1957)
6. LE Moore, DR Baris, JD Figueroa, M Garcia-Closas, MR Karagas, MR Schwenn, AT Johnson, JH Lubin, DW Hein, CL Dagnall, JS Colt, M Kida, MA Jones, AR Schned, SS Cherala, SJ Chanock, KP Cantor, DT Silverman, N Rothman: GSTM1 null and NAT2 slow acetylation genotypes, smoking intensity and bladder cancer risk: results from the New England bladder cancer study and NAT2 meta-analysis. Carcinogenesis 32, 182-189 (2011)
7. RG Hall, RD Leff, T Gumbo: Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 29, 1468-1481 (2009)
8. K Fukino, Y Sasaki, S Hirai, T Nakamura, M Hashimoto, F Yamagishi, K Ueno: Effects of Nacetyltransferase 2 (NAT2), CYP2E1 and glutathione- Stransferase (GST) genotypes on the serum concentrations of isoniazid and metabolites in tuberculosis patients. J Toxicol Sci 33, 187-195 (2008)
9. W Weistenhöfer, M Blaszkewicz, HM Bolt, K Golka: N-Acetyltransferase-2 and medical history in bladder cancer cases with a suspected occupational disease (BK 1301) in Germany. J Toxicol Environ Health A 71, 906-910 (2008)
10. K Golka, T Seidel, H Dietrich, G Roth, C Rötzel, R Thier, F Geller, T Reckwitz, H Schulze: Occupational and non-occupational risk factors in bladder cancer patients in an industrialized area located in former East-Germany. Aktuelle Urol 36, 417-422 (2005)
11. K Golka, V Prior, M Blaszkewicz, HM Bolt: The enhanced bladder cancer susceptibility of NAT2 slow acetylators towards aromatic amines: a review considering ethnic differences. Toxicol Lett 2002 128, 229-241 (2002)
12. K Golka, W Weistenhöfer, P Jedrusik, F Geller, M Blaszkewicz, HM Bolt: N-Acetyltransferase 2 phenotype in painters with bladder cancer and controls. Ann Acad Med Singapore 30, 464-467 (2001)
13. K Golka, T Reckwitz, M Kempkes, I Cascorbi, M Blaskewicz, SE Reich, I Roots, J Soekeland, H Schulze, HM Bolt: N-Acetyltransferase 2 (NAT2) and glutathione S-transferase μ (GSTM1) in bladder-cancer patients in a highly industrialized area. Int J Occup Environ Health 3, 105-110 (1997)
14. K Golka, V Prior, M Blaszkewicz, I Cascorbi, W Schöps, G Kierfeld, I Roots, HM Bolt: Occupational history and genetic N-acetyltransferase polymorphism in urothelial cancer patients of Leverkusen, Germany. Scand J Work Environ Health 22, 332-338 (1996)
15. M Garcia-Closas, N Malats, D Silverman, M Dosemeci, M Kogevinas, DW Hein, A Tardon, C Serra, A Carrato, R Garcia-Closas, J Lloreta, G Castaño-Vinyals, M Yeager, R Welch, S Chanock, N Chatterjee, S Wacholder, C Samanic, M Torà, F Fernández, FX Real, N Rothman: NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 366, 649-659 (2005)
16. RJ Hung, P Boffetta, P Brennan, C Malaveille, A Hautefeuille, F Donato, U Gelatti, M Spaliviero, D Placidi, A Carta, A Scotto di Carlo, S Porru: GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high-risk population. Int J Cancer 110, 598-604 (2004)
17. QW Ma, GF Lin, JG Chen, CQ Xiang, WC Guo, K Golka, JH Shen: Polymorphism of N-acetyltransferase 2 (NAT2) gene polymorphism in Shanghai population: occupational and non-occupational bladder cancer patient groups. Biomed Environ Sci 17, 291-298 (2004)
18. R Thier, T Brüning, PH Roos, HP Rihs, K Golka, Y Ko, HM Bolt: Markers of genetic susceptibility in human environmental hygiene and toxicology: The role of selected CYP, NAT and GST genes. Int J Hyg Environ Health 206, 149-171 (2003)
19. YS Huang, HD Chern, WJ Su, JC Wu, SL Lai, SY Yang, FY Chang, SD Lee: Polymorphism of the Nacetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 35, 883-889 (2002)
20. P Vineis, D Marinelli, H Autrup, J Brockmöller, I Cascorbi, AK Daly, K Golka, H Okkels, A Risch, N Rothman, E Sim, E Taioli: Current smoking, occupation, N-acetyltransferase-2 and bladder cancer: a pooled analysis of genotype-based studies. Cancer Epidemiol Biomarkers Prev 10, 1249-1252 (2001)
21. JG Hengstler, M Arand, ME Herrero, F Oesch: Polymorphisms of N-acetyltransferases, glutathione Stransferases, microsomal epoxide hydrolase and sulfotransferases: influence on cancer susceptibility. Recent Results Cancer Res 154, 47-85 (1998)
22. JA Agundez: Polymorphisms of human Nacetyltransferases and cancer risk. Curr Drug Metab 9, 520-531 (2008)
23. DW Hein: N-Acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene 25, 1649-1658 (2006)
24. N Rothman, M Garcia-Closas, N Chatterjee, N Malats, X Wu, JD Figueroa, FX Real, D Van Den Berg, G Matullo, D Baris, M Thun, LA Kiemeney, P Vineis, I De Vivo, D Albanes, MP Purdue, T Rafnar, MA Hildebrandt, AE Kiltie, O Cussenot, K Golka, R Kumar, JA Taylor, JI Mayordomo, KB Jacobs, M Kogevinas, A Hutchinson, Z Wang, YP Fu, L Prokunina-Olsson, L Burdett, M Yeager, W Wheeler, A Tardón, C Serra, A Carrato, R Garcia-Closas, J Lloreta, A Johnson, M Schwenn, MR Karagas, A Schned, G Andriole Jr, R Grubb III, A Black, EJ Jacobs, WR Diver, SM Gapstur, SJ Weinstein, J Virtamo, VK Cortessis, M Gago-Dominguez, MC Pike, MC Stern, JM Yuan, DJ Hunter, M McGrath, CP Dinney, B Czerniak, M Chen, H Yang, SH Vermeulen, KK Aben, JA Witjes, RR Makkinje, P Sulem, S Besenbacher, K Stefansson, E Riboli, P Brennan, S Panico, C Navarro, NE Allen, HB Bueno-de-Mesquita, D Trichopoulos, N Caporaso, MT Landi, F Canzian, B Ljungberg, A Tjonneland, F Clavel-Chapelon, DT Bishop, MT Teo, MA Knowles, S Guarrera, S Polidoro, F Ricceri, C Sacerdote, A Allione, G Cancel-Tassin, S Selinski, JG Hengstler, H Dietrich, T Fletcher, P Rudnai, E Gurzau, K Koppova, SC Bolick, A Godfrey, Z Xu, JI Sanz-Velez, MD Garcia-Prats, M Sanchez, G Valdivia, S Porru, S Benhamou, RN Hoover, JF Fraumeni Jr, DT Silverman, SJ Chanock: A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet 42, 978-984 (2010)
25. JM Walraven, Y Zang, JO Trent, DW Hein: Structure/function evaluations of single nucleotide polymorphisms in human N-acetyltransferase 2. Curr Drug Metab 9, 471-486 (2008)
26. DM Grant: Structures of human arylamine Nacetyltransferases. Curr Drug Metab 9, 465-70 (2008)
27. DM Grant: Molecular genetics of the Nacetyltransferases. Pharmacogenetics 3, 45-50 (1993)
28. DM Grant, M. Blum and U.A. Meyer: Polymorphisms of N-acetyltransferase genes. Xenobiotica 22, 1073-1081 (1992)
29. I Cascorbi, I Roots: Pitfalls in N-acetyltransferase 2 genotyping. Pharmacogenetics 9, 123-127 (1999)
30. DW Hein, MA Doll, TD Rustan, RJ Ferguson: Metabolic activation of N-hydroxyarylamines and Nhydroxyarylamides by 16 recombinant human NAT2 allozymes: effects of 7 specific NAT2 nucleic acid substitutions. Cancer Res 55, 3531-3536 (1995)
31. DW Hein, RJ Ferguson, MA Doll, TD Rustan, K Gray: Molecular genetics of human polymorphic Nacetyltransferase: enzymatic analysis of 15 recombinant wild-type, mutant and chimeric NAT2 allozymes. Hum Mol Genet 3, 729-734 (1994)
32. DW Hein, MA Doll, TD Rustan, K Gray, Y Feng, RJ Ferguson, DM Grant: Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis 14, 1633-1638 (1993)
33. KPVatsis, WW Weber, DA Bell, JM Dupret, DAP Evans, DM Grant, DW Hein, HJ Lin, UA Meyer, MV Relling, E Sim, T Suzuki, Y Yamazoe: Nomenclature for N-acetyltransferases. Pharmacogenetics 5, 1-17 (1995)
34. DA Bell, JA Taylor, MA Butler, EA Stephens, J Wiest, LH Brubaker, FF Kadlubar, GW Lucier: Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slowacetylator allele common in African-Americans. Carcinogenesis 14, 1689-1692 (1993)
35. M Blum, A Demierre, DM Grant, M Heim, UA Meyer: Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci U S A 88, 5237-41 (1991)
36. D Hickman, E Sim: N-Acetyltransferase polymorphism. Comparison of phenotype and genotype in humans. Biochem Pharmacol 42, 1007-1014 (1991)
37. JA Agundez, K Golka, C Martinez, S Selinski, M Blaszkewicz, E Garcia-Martin: Unraveling ambiguous NAT2 genotyping data. Clin Chem 54, 1390-1394 (2008)
38. K Golka, M Blaszkewicz, M Samimi, HM Bolt, S Selinski: Reconstruction of N-acetyltransferase 2 haplotypes using PHASE. Arch Toxicol 82, 265-270 (2008)
39. HM Bolt, S Selinski, D Dannappel, M Blaszkewicz, K Golka: Re-investigation of the concordance of human NAT2 phenotypes and genotypes. Arch Toxicol 79, 196-200 (2008)
40. AC Deitz, N Rothman, TR Rebbeck, RB Hayes, WH Chow, W Zheng, DW Hein, M Garcia-Closas: Impact of misclassification in genotype-exposure interaction studies: example of N-acetyltransferase 2 (NAT2), smoking, and bladder cancer. Cancer Epidemiol Biomarkers Prev 13, 1543-1546 (2004)
41. I Cascorbi, N Drakoulis, J Brockmöller, A Maurer, K Sperling, I Roots: Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 57, 581-592 (1995)
42. DW Hein, DM Grant, E Sim: Update on consensus arylamine N-acetyltransferase gene nomenclature. Pharmacogenetics 10, 291-292 (2000)
43. DW Hein, S Boukouvala, DM Grant, RF Minchin, E Sim: Changes in consensus arylamine N-acetyltransferase gene nomenclature. Pharmacogenet Genomics 18, 367-368 (2008)
44. Arylamine N-acetyltransferase Nomenclature Committee. Update November 1, 2010. http://www.louisville.edu/medschool/pharmacology/NAT.h tml (accessed Feb 2, 2011)
45. Y Zang, MA Doll, S Zhao, JC States, DW Hein: Functional characterization of single-nucleotide polymorphisms and haplotypes of human Nacetyltransferase 2. Carcinogenesis 28, 1665-1671 (2007)
46. DW Hein, MA Doll, AJ Fretland, MA Leff, SJ Webb, GH Xiao, US Devanaboyina, NA Nangju, Y Feng: Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 9, 29-42 (2000)
47. JA Agundez, JG Menaya, R Tejeda, F Lago, M Chavez, J Benitez: Genetic analysis of the NAT2 and CYP2D6 polymorphisms in white patients with non-insulin dependent diabetes mellitus. Pharmacogenetics 6, 465-472 (1996)
48. MA Leff, AJ Fretland, MA Doll, DW Hein: Novel human N-acetyltransferase 2 alleles that differ in mechanism for slow acetylator phenotype. J Biol Chem 274, 34519-34522 (1999)
49. A Sabbagh, A Langaney, P Darlu, N Gerard, R Krishnamoorthy, ES Poloni: Worldwide distribution of NAT2 diversity: implications for NAT2 evolutionary history. BMC Genet 9, 21 (2008)
50. E Garcia-Martin: Interethnic and intra-ethnic variability of NAT2 single nucleotide polymorphisms. Curr Drug Metab 9, 487-497 (2008)
51. F Luca, G Bubba, M Basile, R Brdicka, E Michalodimitrakis, O Rickards, G Vershubsky, L Quintana-Murci, AI Kozlov, A Novelletto: Multiple advantageous amino acid variants in the NAT2 gene in human populations. PLoS One 3, e3136 (2008)
52. LF Jorge-Nebert, M Eichelbaum, EU Griese, T Inaba, TD Arias: Analysis of six SNPs of NAT2 in Ngawbe and Embera Amerindians of Panama and determination of the Embera acetylation phenotype using caffeine. Pharmacogenetics 12, 39-48 (2002)
53. H Magalon, E Patin, F Austerlitz, T Hegay, A Aldashev, L Quintana-Murci, E Heyer: Population genetic diversity of the NAT2 gene supports a role of acetylation in human adaptation to farming in Central Asia. Eur J Hum Genet 16, 243-251 (2008)
54. E Patin, LB Barreiro, PC Sabeti, F Austerlitz, F Luca, A Sajantila, DM Behar, O Semino, A Sakuntabhai, N Guiso, B Gicquel, K McElreavey, RM Harding, E Heyer, L Quintana-Murci: Deciphering the ancient and complex evolutionary history of human arylamine N-acetyltransferase genes. Am J Hum Genet 78, 423-436 (2006)
55. E Patin, C Harmant, KK Kidd, J Kidd, A Froment, SQ Mehdi, L Sica, E Heyer, L Quintana-Murci: Sub-Saharan African coding sequence variation and haplotype diversity at the NAT2 gene. Hum Mutat 27, 720 (2006)
56. A Sabbagh, P Darlu: Inferring haplotypes at the NAT2 locus: The computational approach. BMC Genet 6, 30 (2005)
57. M Blaszkewicz, D Dannappel, R Thier, J Lewalter: N-Acetyltransferase 2 (genotyping). In: Analyses of hazardous substances in biological materials, vol 9. Special issue: Markers of susceptibility. Eds: J Angerer, M Müller, T Weiss et al. Eds. Wiley-VCH, Weinheim, Germany (2004)
58. I Cascorbi, J Brockmöller, PM Mrozikiewicz, S Bauer, R Loddenkemper, I Roots: Homozygous rapid arylamine N-acetyltransferase NAT2 genotype as susceptibility factor for lung cancer. Cancer Res 56, 3961-3966 (1996)
59. M Stephens, NJ Smith, P Donnelly: A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68, 978-89 (2001)
60. M. Stephens and P. Donnelly: A comparison of Bayesian methods for haplotype reconstruction. Am J Hum Genet 73, 1162-1169 (2003)
61. M Stephens, P Scheet: Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am J Hum Genet 76, 449-462 (2005)
62. J Marchini, D Cutler, N Patterson, M Stephens, E Eskin, E Halperin, S Lin, ZS Qin, HM Munro, GR Abecasis, P Donnelly and the International HapMap Consortium: A comparison of phasing algorithms for trios and unrelated individuals. Am J Hum Genet 78, 437-450 (2006)
63. N Li, M Stephens: Modeling linkage disequilibrium and identifying recombination hotspots using singlenucleotide polymorphism data. Genetics 165, 2213-2233 (2003)
64. M Garcia-Closas, DW Hein, D Silverman, N Malats, M Yeager, K Jacobs, MA Doll, JD Figueroa, D Baris, M Schwenn, M Kogevinas, A Johnson, N Chatterjee, LE Moore, T Moeller, FX Real, S Chanock, N Rothman: A single nucleotide polymorphism tags variation in the arylamine N-acetyltransferase 2 phenotype in populations of European background. Pharmacogenet Genomics 21, 231-236 (2011)
65. P Boffetta: Tobacco smoking and risk of bladder cancer. Scand J Urol Nephrol Suppl 42(S218), 45-54 (2008)
66. MP Zeegers, RA Goldbohm, PA Van Den Brandt: A prospective study on active and environmental tobacco smoking and bladder cancer risk. Cancer Causes Control 13, 83-90 (2002)
67. MP Zeegers, FE Tan, E Dorant, PA Van Den Brandt: The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer 89, 630-639 (2000)
68. GL Delclos, SP Lerner: Occupational risk factors. Scandinavian Journal of Urology and Nephrology Suppl 42(S218), 58-63 (2008)
69. RC Reulen, E Kellen, F Buntinx, M Brinkman, MP Zeegers: A meta-analysis on the association between bladder cancer and occupation. Scandinavian Journal of Urology and Nephrology Suppl 42(S218), 64-78 (2008)
70. I Cascorbi, I Roots, J Brockmöller: Association of NAT1 and NAT2 polymorphisms to urinary bladder cancer: significantly reduced risk in subjects with NAT1 10. Cancer Res 61, 5051-5056 (2001)
71. A Risch, DM Wallace, S Bathers, E Sim: Slow Nacetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum Mol Genet 4, 231-236 (1995)
72. J Talbot, LA Magno, CV Santana, SM Sousa, PR Melo, RX Correa, G Di Pietro, F Rios-Santos: Interethnic diversity of NAT2 polymorphisms in Brazilian admixed populations. BMC Genet 11, 87 (2010)
73. L Excoffier, G Laval, S Schneider: Arlequin ver. 3.0: An integrated software package for population genetics data analysis. Evolutionary Bioinformatics Online 1, 47-50 (2005)
74. P Scheet, M Stephens: A fast and flexible statistical model for large-scale population genotype data: applications to inferring missing genotypes and haplotypic phase. Am J Hum Genet 78, 629-644 (2006)
75. T Niu, ZS Qin, X Xu, JS Liu: Bayesian haplotype inference for multiple linked single-nucleotide polymorphisms. Am J Hum Genet 70, 157-169 (2002)
76. ZS Qin, T Nui, JS Liu: Partition-ligation-expectation-maximization algorithm for haplotype inference with single-nucleotide polymorphisms. Am J Hum Genet 71, 1242-1247 (2002)
77. RM Salem, J Wessel, NJ Schork: A comprehensive literature review of haplotyping software and methods for use with unrelated individuals. Hum Genomics 2, 39-66 (2005)
78. T Niu: Algorithms for inferring haplotypes. Genet Epidemiol 27, 334-347 (2004)
79. C Coulonges, O Delaneau, M Girard, H Do, R Adkins, J-L Spadoni, J-F Zagury: Computation of haplotypes on SNPs subsets: advantage of the "global method". BMC Genet 7, 50 (2006)
80. L Eronen, F Geerts, H Toivonen: HaploRec: effcient and accurate large-scale reconstruction of haplotypes. BMC Bioinformatics 7, 542 (2006)
81. J Zhang, M Vingron, MR Hoehe: Haplotype reconstruction for diploid populations. Hum Hered 59, 144-156 (2005)
82. RM Adkins: Comparison of the accuracy of methods of computational haplotype inference using a large empirical dataset. BMC Genet 5, 22 (2004)
83. M Jain, S Kumar, P Lal, A Tiwari, UC Ghoshal, B Mittal: Association of genetic polymorphisms of Nacetyltransferase 2 and susceptibility to esophageal cancer in north Indian population. Cancer Invest 25, 340-346 (2007)
84. SC Sak, JH Barrett, AB Paul, DT Bishop, AE Kiltie: DNA repair gene XRCC1 polymorphisms and bladder cancer risk. BMC Genet 8, 13 (2007)
85. S Rabstein, K Unfried, U Ranft, T Illig, M Kolz, HP Rihs, C Mambetova, M Vlad, T Brüning, B Pesch: Variation of the N-acetyltransferase 2 gene in a Romanian and a Kyrgyz population. Cancer Epidemiol Biomarkers Prev 15, 138-141 (2006)
86. IB Kuznetsov, M McDuffie, R Moslehi: A web server for inferring the human N-acetyltransferase-2 (NAT2) enzymatic phenotype from NAT2 genotype. Bioinformatics 25, 1185-1186 (2009)
87. A Sabbagh, P Darlu, M Vidaud: Evaluating NAT2PRED for inferring the individual acetylation status from unphased genotype data. BMC Med Genet 10, 148 (2009)
88. PM Mrozikiewicz, I Cascorbi, J Brockmöller, I Roots: Determination and allelic allocation of seven nucleotide transitions within the arylamine N-acetyltransferase gene in the Polish population. Clin Pharmacol Ther 59, 376-382 (1996)
89. EA Gaikovitch, I Cascorbi, PM Mrozikiewicz, J Brockmöller, R Frötschl, K Köpke, T Gerloff, JN Chernov, I Roots: Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of Pglycoprotein in a Russian population. Eur J Clin Pharmacol 59, 303-312 (2003)
90. S Fuselli, RH Gilman, SJ Chanock, SL Bonatto, G De Stefano, CA Evans, D Labuda, D Luiselli, FM Salzano, G Soto, G Vallejo, A Sajantila, D Pettener, E Tarazona-Santos: Analysis of nucleotide diversity of NAT2 coding region reveals homogeneity across Native American populations and high intra-population diversity. Pharmacogenomics J 7, 144-152 (2007)
91. C Martinez, JA Agundez, M Olivera, A Llerena, R Ramirez, M Hernández, J Benitez: Influence of genetic admixture on polymorphisms of drug-metabolizing enzymes: analyses of mutations on NAT2 and C gamma P2E1 genes in a mixed Hispanic population. Clin Pharmacol Ther 63, 623-628 (1998)
92. RL Teixeira, AB Miranda, AG Pacheco, MQ Lopes, J Fonseca-Costa, MF Rabahi, HM Melo, AL Kritski, FC Mello, PN Suffys, AR Santos: Genetic profile of the arylamine Nacetyltransferase 2 coding gene among individuals from two different regions of Brazil.Mutat Res 624, 31-40 (2007)
93. L Le Marchand, L Sivaraman, AA Franke, LJ Custer, LR Wilkens, AF Lau, RV Cooney: Predictors of Nacetyltransferase activity: should caffeine phenotyping and NAT2 genotyping be used interchangeably in epidemiological studies? Cancer Epidemiol Biomarkers Prev 5, 449-455 (1996)
94. S Selinski, M Blaszkewicz, ML Lehmann, D Ovsiannikov, O Moormann, C Guballa, A Kress, MC Truß, H Gerullis, T Otto, D Barski, G Niegisch, P Albers, S Frees, W Brenner, JW Thüroff, M Angeli-Greaves, T Seidel, G Roth, H Dietrich, R Ebbinghaus, HM Prager, HM Bolt, M Falkenstein, A Zimmermann, T Klein, T Reckwitz, HC Roemer, D Löhlein, W Weistenhöfer, W Schöps, SAH Rizvi, M Aslam, G Banfi, I Romics, M Steffens, AB Ekici, A Winterpacht, K Ickstadt, H Schwender, JG Hengstler, K Golka: Genotyping NAT2 with only two SNPs (rs1041983 and rs1801280) outperforms the tagging SNP rs1495741 and is equivalent to the conventional 7-SNP NAT2 genotype. Pharmacogenet Genomics 21, 673-678 (2011)
95. DM Grant, BK Tang, W Kalow: A simple test for acetylator phenotype using caffeine. Br J Clin Pharmacol 17, 459-464 (1984)
96. M Blaszkewicz: N-Acetyltransferase 2 (phenotyping: caffeine test) In: Analyses of hazardous substances in biological materials, vol 9. Special issue: Markers of susceptibility. Eds: J Angerer, M Müller, T Weiss et al. Wiley-VCH, Weinheim, Germany (2004)
97. JAG Agundez: NAT2 genotyping: equilibrium between accuracy and feasibility in routine analyses. J Appl Res 3(2), 1-6 (2003)